Huadong Medicine Company Limited operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Huadong Medicine Company Limited with three other
drug stores in Asia:
Hokuyaku Takeyama Holdings, Inc
sales of 225.15 billion Japanese Yen [US$2.02 billion]
of which 72%
was Pharmaceutical Business),
Vital KSK Holdings Incorporation
(621.04 billion Japanese Yen [US$5.56 billion]
of which 95%
was Pharmaceuticals Sales), and
based in Malaysia
(2.19 billion Malaysian Ringgits [US$494.59 million]
of which 98%
was Logistics and Distribution).
Huadong Medicine Company Limited reported sales of 25.38 billion Chinese Renmimbi (US$3.69 billion)
December of 2016.
increase of 16.8%
versus 2015, when the company's sales were 21.73 billion Chinese Renmimbi.
Sales at Huadong Medicine Company Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 128%).
Sales of Manufacturing saw an increase
17.8% in 2016, from
4.97 billion Chinese Renmimbi to 5.85 billion Chinese Renmimbi.
Not all segments of Huadong Medicine Company Limited experienced an increase in sales in 2016:
sales of Other Operating fell 10.1% to 33.80 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).